Qualitative pilot study evaluates biocompatibility and regenerative potential of biocement in porcine osteochondral defects, highlighting possible therapeutic advances.
The treatment of osteochondral defects still poses a challenge, despite the fact that there are currently many methods and various materials designed for the regeneration of these tissues. The aim of our study was to evaluate the biocompatibility and bioactive potential of an innovative biocement enriched with manuka honey and α-tricalcium phosphate in a porcine model, with a focus on subchondral bone regeneration. Osteochondral defects of the medial femoral condyle were treated with the tested biocement in five animals, and five additional animals served as controls (untreated defect). After six months of observation, the regenerative potential of the therapeutic strategy was evaluated macroscopically, using imaging methods (X-ray, CT, and MRI) and histological examination. The studied biomaterial showed no cytotoxicity and proved to be biocompatible. In the in vivo system, based on imaging and histological methods, a typical trabecular organization with cellular elements has been observed in all animals treated with the tested biocement, indicating active remodeling and maturation processes. In animals with untreated defects, incomplete healing of the bone defect occurred, with limited areas of trabecular bone and incomplete boundaries between the cartilage and subchondral bone. Our pilot study, employing a multi-method approach to investigate the in vivo effects of a novel biocement on bone tissue regeneration, may highlight the potential contribution of biomaterials to the development of new therapeutic strategies in the context of osteochondral regeneration.
No takes yet. Share an insight, caveat, or question.
Korim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: